12:00 AM
 | 
Jan 21, 2013
 |  BioCentury  |  Finance

Monthly money

Once-monthly human growth hormone draws Aisling to invest in Versartis
Monthly money

Versartis Inc. expects last week's $25 million series C round will get it to a Phase Ib/IIa data event for a long-acting recombinant human growth hormone to treat growth hormone deficiency. The product's once-monthly dosing would trump both the marketed daily version of hGH and the handful of once-weekly versions in the clinic.

The company's VRS-317 rhGH was developed using...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >